These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

641 related items for PubMed ID: 25029569

  • 21. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
    Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, Worchel J.
    Drug Saf; 2006; 29(7):621-32. PubMed ID: 16808554
    [Abstract] [Full Text] [Related]

  • 22. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, García-Rodríguez LA.
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
    [Abstract] [Full Text] [Related]

  • 23. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.
    Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
    [Abstract] [Full Text] [Related]

  • 24. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.
    Andersohn F, Schade R, Suissa S, Garbe E.
    Stroke; 2006 Jul; 37(7):1725-30. PubMed ID: 16728684
    [Abstract] [Full Text] [Related]

  • 25. Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
    Cunnington M, Webb D, Qizilbash N, Blum D, Mander A, Funk MJ, Weil J.
    Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):601-8. PubMed ID: 18383442
    [Abstract] [Full Text] [Related]

  • 26. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
    Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Triadafilopoulos G, SUCCESS-I Investigators.
    Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
    [Abstract] [Full Text] [Related]

  • 27. Risk of cardiovascular events associated with selective COX-2 inhibitors.
    Mukherjee D, Nissen SE, Topol EJ.
    JAMA; 2006 Mar; 286(8):954-9. PubMed ID: 11509060
    [Abstract] [Full Text] [Related]

  • 28. Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo.
    Bingham CO, Smugar SS, Wang H, Tershakovec AM.
    Rheumatology (Oxford); 2009 Sep; 48(9):1122-7. PubMed ID: 19589894
    [Abstract] [Full Text] [Related]

  • 29. The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor.
    Warner JJ, Weideman RA, Kelly KC, Brilakis ES, Banerjee S, Cunningham F, Harford WV, Kazi S, Little BB, Cryer B.
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):252-60. PubMed ID: 18787084
    [Abstract] [Full Text] [Related]

  • 30. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
    Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL.
    Ann Intern Med; 2005 Feb 01; 142(3):157-64. PubMed ID: 15684203
    [Abstract] [Full Text] [Related]

  • 31. Factors associated with celecoxib and rofecoxib utilization.
    Rawson NS, Nourjah P, Grosser SC, Graham DJ.
    Ann Pharmacother; 2005 Apr 01; 39(4):597-602. PubMed ID: 15755796
    [Abstract] [Full Text] [Related]

  • 32. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
    Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA.
    Lancet; 2005 Apr 01; 365(9458):475-81. PubMed ID: 15705456
    [Abstract] [Full Text] [Related]

  • 33. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP, Deray G, Héloire F.
    Presse Med; 2006 Sep 01; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
    [Abstract] [Full Text] [Related]

  • 34. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.
    Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M.
    Lancet; 2006 Sep 01; 364(9450):2021-9. PubMed ID: 15582059
    [Abstract] [Full Text] [Related]

  • 35. Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
    Elliott WJ.
    Curr Hypertens Rep; 2010 Aug 01; 12(4):258-66. PubMed ID: 20524091
    [Abstract] [Full Text] [Related]

  • 36. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S.
    Arthritis Rheum; 2006 May 01; 54(5):1378-89. PubMed ID: 16645966
    [Abstract] [Full Text] [Related]

  • 37. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.
    Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C.
    BMJ; 2006 Jun 03; 332(7553):1302-8. PubMed ID: 16740558
    [Abstract] [Full Text] [Related]

  • 38. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA.
    Arthritis Rheum; 2006 Nov 03; 54(11):3390-8. PubMed ID: 17075817
    [Abstract] [Full Text] [Related]

  • 39. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
    McCormack PL.
    Drugs; 2011 Dec 24; 71(18):2457-89. PubMed ID: 22141388
    [Abstract] [Full Text] [Related]

  • 40. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
    Mallen SR, Essex MN, Zhang R.
    Curr Med Res Opin; 2011 Jul 24; 27(7):1359-66. PubMed ID: 21561397
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.